Drug Information

Drug General Information
Drug ID
D03AJX
Former ID
DNC001157
Drug Name
PS-341
Drug Type
Small molecular drug
Indication Mantle cell lymphoma [ICD9: 200.4, 202.8, 203.0, 208.9; ICD10:C81-C86, C85.7, C90.0, C91-C95] Approved [546307], [551871]
Structure
Download
2D MOL

3D MOL
Formula
C19H25BN4O4
Canonical SMILES
B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O
InChI
1S/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m1/s1
InChIKey
GXJABQQUPOEUTA-NVXWUHKLSA-N
CAS Number
CAS 179324-69-7
PubChem Compound ID
93860
PubChem Substance ID
44424531, 49895087, 50113272, 50726121, 57335697, 92719226, 103565488, 104411215, 124893550, 126575146, 126620978, 126658246, 126667091, 126727554, 134338534, 135051251, 135727461, 137001833, 140705866, 141088999, 160963536, 196109699, 223662143, 226395803, 243055978, 251971017, 252671873
ChEBI ID
ChEBI:52717
SuperDrug ATC ID
L01XX32
SuperDrug CAS ID
cas=179324697
Target and Pathway
Target(s) Nuclear factor NF-kappa-B Target Info Inhibitor [535450]
20S proteasome Target Info Inhibitor [535318]
KEGG Pathway MAPK signaling pathway
NF-kappa B signaling pathway
Osteoclast differentiation
Legionellosis
HTLV-I infection
Epstein-Barr virus infection
Pathways in cancer
Viral carcinogenesis
NetPath Pathway IL5 Signaling Pathway
PANTHER Pathway Apoptosis signaling pathway
B cell activation
Inflammation mediated by chemokine and cytokine signaling pathway
T cell activation
Toll receptor signaling pathway
Pathway Interaction Database IL12-mediated signaling events
Alternative NF-kappaB pathway
PathWhiz Pathway Intracellular Signalling Through Adenosine Receptor A2a and Adenosine
Intracellular Signalling Through Adenosine Receptor A2b and Adenosine
Reactome RIP-mediated NFkB activation via ZBP1
DEx/H-box helicases activate type I IFN and inflammatory cytokines production
TAK1 activates NFkB by phosphorylation and activation of IKKs complex
Interleukin-1 processing
IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR)
IkBA variant leads to EDA-ID
Dectin-1 mediated noncanonical NF-kB signaling
NIK-->noncanonical NF-kB signaling
TRAF6 mediated NF-kB activation
WikiPathways Toll-like receptor signaling pathway
DNA Damage Response (only ATM dependent)
SIDS Susceptibility Pathways
Nuclear Receptors Meta-Pathway
Cytosolic sensors of pathogen-associated DNA
TAK1 activates NFkB by phosphorylation and activation of IKKs complex
EBV LMP1 signaling
TNF alpha Signaling Pathway
TSLP Signaling Pathway
Neural Crest Differentiation
TWEAK Signaling Pathway
RANKL/RANK Signaling Pathway
RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
Interleukin-1 processing
Folate Metabolism
Vitamin B12 Metabolism
Selenium Micronutrient Network
Regulation of toll-like receptor signaling pathway
References
Ref 546307Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007364)
Ref 551871Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 535318Selected novel anticancer treatments targeting cell signaling proteins. Oncologist. 2001;6(6):517-37.
Ref 535450Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood. 2002 Jun 1;99(11):4079-86.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.